Biomarker Standardization and Early Cancer Detection Driving the Global CA 125 Test Market
The global CA 125 Test Market is a crucial diagnostic segment, driven by its established role in the management and monitoring of Ovarian Cancer (OC) and, increasingly, in the differential diagnosis of various benign gynecological conditions. Cancer Antigen 125 (CA 125) is a protein found on the surface of many ovarian cancer cells, and elevated levels in the blood are often used for three main clinical purposes: monitoring treatment response in women with confirmed OC, detecting recurrence after initial therapy, and risk stratification when an adnexal mass is identified via imaging. The primary market catalyst is the increasing global incidence of ovarian cancer, which, due to its often asymptomatic early stages, relies heavily on serum markers like CA 125 (often used in combination with transvaginal ultrasound in risk scoring models like the Risk of Malignancy Index) to…